Increased Prevalence of Gastroesophageal Reflux Disease Boosts Proton Pump Inhibitors Market

For the purpose of treatment of acid-related disorders and heartburn, proton pump inhibitors are the most frequently prescribed type of medication. They block the area of production of acid that lies in the stomach’s parietal cell. Increased prevalence of gastroesophageal reflux disease coupled with growing acceptance of novel methods of drug delivery are adding impetus to the global proton pump inhibitors market over the tenure of forecast.

Get Sample Copy of this Report @ https://www.tmrresearch.com/sample/sample?flag=B&rep_id=6889

Shift toward Over-the-Counter Drugs is Likely to Accentuate its Demand in the Market

In recent times, there has been a rise in the prevalence of symptoms of gastroesophageal reflux diseases. Such symptoms are usually found in individuals with normal basal metabolic index (BMI) but are overweight. Given the augmented prevalence of obesity and associated medical cost for its treatment are likely to support the growth of the global proton pump inhibitors market during the forecast tenure. Furthermore, a growing inclination toward over the counter drugs instead of prescription is another factor that could add impetus to the growth of the market in years to come.

Obesity is an important factor for different chronic diseases, such as specific types of cancer, type 2 diabetes, and cardiovascular diseases. Such diseases often lead to premature death. In addition, there is a growing trend for juvenile obesity amongst adolescents and children, which leads to augmented chances of poor health in these sub groups of human population. As a result of such increased chances of obesity leads to augmented risk of being affected with gastrointestinal and esophageal related health conditions. This offers substantial growth opportunities for the global proton pump inhibitors market.

In the developed countries, such as the United Kingdom, the United States, Germany and others, obesity is a rapidly growing medical condition. Obesity is an important risk factor for gastroesophageal reflux disease, which is likely to offer copious growth opportunities for the global proton pump inhibitors market in forthcoming years.

Check Table of Contents of this Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=6889

Author: Rohit Bhisey

As Head of Marketing at TMR Research, Rohit brings to the table over a decade of experience in market research and Internet marketing. His dedication, perseverance, and passion for perfection have enabled him to achieve immense success in his field. Rohit is an expert at formulating new business plans and strategies to help boost web traffic. His interests lie in writing news articles on technology,healthcare and business.

Leave a Reply